Novavax's experimental COVID-19-influenza combination and standalone influenza vaccines generated a strong immune response in adults aged 65 and older, similar to already approved shots against the ...

Retail investor chatter around vaccine makers Novavax, Moderna, and Pfizer rose on Wednesday, ahead of a closely watched CDC ...

Writing in JAMA, four former governmental officials warn that the Trump administration’s involvement in delaying the approval ...

New members of the ACIP panel raised questions about the evidence supporting COVID vaccines, and signaled plans to look at ...

Novavax's combo and standalone flu vaccines showed strong immune responses and good safety in a Phase 3 trial of adults 65 and older.

After years of updates on COVID-19 vaccines and boosters, it can be confusing to know who should get a shot and when. While a lot of that confusion has to do with the new COVID strains that ...

Novavax, Inc. faces profitability challenges despite a promising tech platform, with uncertain revenue streams. Click for my ...

The Centers for Disease Control and Prevention's vaccine advisory committee is set to meet for the first time since Health ...

The Department of Health and Human Services has defended cuts to vaccine research with statements that mislead on the safety ...

Vaccine businesses seen as valuable parts of pharma groups but government hostility could deter future developments ...

COVID-19 appears to be on the rise in some parts of California as a new, highly contagious subvariant — featuring “razor ...